Journal Article

Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

Herteliu, Claudiu, Balouchi, Abbas, Khang, Young-Ho, Carvalho, Félix, Ribeiro, Daniel Cury, Joukar, Farahnaz, Smith, Mari, Ashagre, Alebachew Fasil, Mohammed, Shafiu, Moreno Velasquez, Ilais, Nachega, Jean B, Rafiei, Alireza, Rawal, Lal, Agarwal, Sanjay Kumar, Irvani, Seyed Sina Naghibi, Ataro, Zerihun, Borzì, Antonio M, Kassaye, Hagazi Gebremedhin, Santos, Itamar S, Owolabi, Mayowa Ojo, James, Spencer L, Khalilov, Rovshan, Neal, Bruce, Rawaf, Salman, Shaikh, Masood Ali, Rothenbacher, Dietrich, Negoi, Ruxandra Irina, Nikbakhsh, Rajan, Nadkarni, Girish N, Andrei, Catalina Liliana, Boloor, Archith, Fischer, Florian, Hosseini, Mostafa, Salem, Hosni, Barquera, Simon, Lotufo, Paulo A, Reiner, Robert C, Bikbov, Boris, Hay, Simon I, Hasan, Mehedi, Waheed, Yasir, Murray, Chris J L, Poustchi, Hossein, Meheretu, Hailemariam Abiy Alemu, Ramezanzadeh, Kiana, Noubiap, Jean Jacques, Abdoli, Amir, Silva, Diego Augusto Santos, Ärnlöv, Johan, Olagunju, Andrew T, Kasaeian, Amir, Morales, Linda, Soheili, Amin, Saadatagah, Seyedmohammad, Gebresillassie, Begashaw Melaku, Islam, Sheikh Mohammed Shariful, Ullah, Irfan

2020

Overview

Health system planning requires careful assessment of chronic kidney disease (CKD) epidemiology, but data for morbidity and mortality of this disease are scarce or non-existent in many countries. We estimated the global, regional, and national burden of CKD, as well as the burden of cardiovascular disease and gout attributable to impaired kidney function, for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. We use the term CKD to refer to the morbidity and mortality that can be directly attributed to all stages of CKD, and we use the term impaired kidney function to refer to the additional risk of CKD from cardiovascular disease and gout. The main data sources we used were published literature, vital registration systems, end-stage kidney disease registries, and household surveys. Estimates of CKD burden were produced using a Cause of Death Ensemble model and a Bayesian meta-regression analytical tool, and included incidence, prevalence, years lived with disability, mortality, years of life lost, and disability-adjusted life-years (DALYs). A comparative risk assessment approach was used to estimate the proportion of cardiovascular diseases and gout burden attributable to impaired kidney function. Globally, in 2017, 1·2 million (95% uncertainty interval [UI] 1·2 to 1·3) people died from CKD. The global all-age mortality rate from CKD increased 41·5% (95% UI 35·2 to 46·5) between 1990 and 2017, although there was no significant change in the age-standardised mortality rate (2·8%, −1·5 to 6·3). In 2017, 697·5 million (95% UI 649·2 to 752·0) cases of all-stage CKD were recorded, for a global prevalence of 9·1% (8·5 to 9·8). The global all-age prevalence of CKD increased 29·3% (95% UI 26·4 to 32·6) since 1990, whereas the age-standardised prevalence remained stable (1·2%, −1·1 to 3·5). CKD resulted in 35·8 million (95% UI 33·7 to 38·0) DALYs in 2017, with diabetic nephropathy accounting for almost a third of DALYs. Most of the burden of CKD was concentrated in the three lowest quintiles of Socio-demographic Index (SDI). In several regions, particularly Oceania, sub-Saharan Africa, and Latin America, the burden of CKD was much higher than expected for the level of development, whereas the disease burden in western, eastern, and central sub-Saharan Africa, east Asia, south Asia, central and eastern Europe, Australasia, and western Europe was lower than expected. 1·4 million (95% UI 1·2 to 1·6) cardiovascular disease-related deaths and 25·3 million (22·2 to 28·9) cardiovascular disease DALYs were attributable to impaired kidney function. Kidney disease has a major effect on global health, both as a direct cause of global morbidity and mortality and as an important risk factor for cardiovascular disease. CKD is largely preventable and treatable and deserves greater attention in global health policy decision making, particularly in locations with low and middle SDI. Bill & Melinda Gates Foundation.

• Publisher: Elsevier Ltd,Elsevier Limited,Elsevier
• Subject: Africa - epidemiology / Age / Asia - epidemiology / Australasia - epidemiology / Bayes Theorem / Bayesian analysis / Cardiovascular disease / Cardiovascular diseases / Cardiovascular Diseases - epidemiology / Cardiovascular Diseases - mortality / Cardiovascular Diseases - physiopathology / Cause of Death / Charities / Decision making / Developing countries / Diabetes / Diabetes mellitus / Diabetic Nephropathies - epidemiology / Diabetic Nephropathies - physiopathology / Diabetic nephropathy / End-stage renal disease / Epidemiology / Estimates / Europe - epidemiology / Global Burden of Disease / Global health / Gout / Gout - epidemiology / Gout - physiopathology / Health and Welfare / Health policy / Health Surveys / Hemodialysis / Humans / Hypertension / Hälsa och välfärd / Incidence / Kidney diseases / Kidneys / Latin America - epidemiology / LDCs / Morbidity / Mortality / Nephropathy / North America - epidemiology / Oceania - epidemiology / Prevalence / Quality-Adjusted Life Years / Registries / Regression analysis / Renal Insufficiency, Chronic - epidemiology / Renal Insufficiency, Chronic - mortality / Renal Insufficiency, Chronic - physiopathology / Renal replacement therapy / Risk analysis / Risk Assessment / Risk factors